This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Erik A. Lippa, MD; Hans A. von Denffer, MD; Hans M. Hofmann, MD; Françoise L. Brunner-Ferber, PhD

Arch Ophthalmol. 1988;106(12):1694-1696.

Abstract
• A three-dose, randomized, double-masked, parallel, placebo-controlled ocular tolerance study was undertaken in 12 healthy, normal volunteers with the water-soluble, topical carbonic anhydrase inhibitor MK-927. To our knowledge, this constitutes the first administration of MK-927 to humans. Ten subjects received three drops of 2% MK-927 ophthalmic solution and two subjects received three drops of placebo (vehicle) in one randomly selected eye. Local tolerance of 2% MK-927 was acceptable and supports further clinical trials in patients. Significant intraocular pressure (IOP)-lowering activity was noted when comparing IOP four hours after first dose with that 20 hours predose in the treated eye of subjects receiving MK-927 (mean percent change in IOP, –29.7%; mean change in IOP, –4.6 mm Hg) as opposed to the same comparison for the contralateral, untreated eye (–7.2% and –1.3 mm Hg, respectively). In the two subjects treated with placebo, IOP-lowering activity was not seen in either the placebo-treated eye (–0.4%) or the contralateral, untreated eye (+3.1%).

Author Affiliations
From the Clinical Research Department, Merck Sharp & Dohme Research Laboratories, West Point, Pa (Dr Lippa); the Department of Ophthalmology, Technical University of Munich (Drs von Denffer and Hofmann); and the Clinical Pharmacology Department, Merck Sharp & Dohme Research Laboratories, Rahway, NJ (Dr Brunner-Ferber).

Footnotes
Accepted for publication Aug 19, 1988.

Reprint requests to Clinical Research, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486 (Dr Lippa).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma
Schmidt et al.
Br J Ophthalmol 1998;82:758-762.
ABSTRACT | FULL TEXT  

Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor
Wilkerson et al.
Arch Ophthalmol 1993;111:1343-1350.
ABSTRACT  

Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?
Rossetti et al.
Arch Ophthalmol 1993;111:96-103.
ABSTRACT  

MK-507 (L-671,152), a Topically Active Carbonic Anhydrase Inhibitor, Reduces Aqueous Humor Production in Monkeys
Wang et al.
Arch Ophthalmol 1991;109:1297-1299.
ABSTRACT  

Topically Active Carbonic Anhydrase Inhibitors for Glaucoma
Podos and Serle
Arch Ophthalmol 1991;109:38-40.
ABSTRACT  

Multiple-Dose, Dose-Response Relationship for the Topical Carbonic Anhydrase Inhibitor MK-927
Lippa et al.
Arch Ophthalmol 1991;109:46-49.
ABSTRACT  

Multiple-Dose Efficacy Comparison of the Two Topical Carbonic Anhydrase Inhibitors Sezolamide and MK-927
Bron et al.
Arch Ophthalmol 1991;109:50-53.
ABSTRACT  

MK-927, A Topical Carbonic Anhydrase Inhibitor: Dose Response and Reproducibility
Serle et al.
Arch Ophthalmol 1990;108:838-841.
ABSTRACT  

MK-927: A Topical Carbonic Anhydrase Inhibitor: Dose Response and Duration of Action
Higginbotham et al.
Arch Ophthalmol 1990;108:65-68.
ABSTRACT  

MK-927: A Topically Effective Carbonic Anhydrase Inhibitor in Patients
Bron et al.
Arch Ophthalmol 1989;107:1143-1146.
ABSTRACT